Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ

8 Mar 2019

Abstract excerpt

// Masami Iwasa 1 , Takeshi Harada 1 , Asuka Oda 1 , Ariunzaya Bat-Erdene 1 , Jumpei Teramachi 2 , Hirofumi Tenshin 3 , Mohannad Ashtar 3 , Masahiro Oura 1 , Kimiko Sogabe 1 , Kengo Udaka 1 , Shiro Fujii 1 , Shingen Nakamura 1 , Hirokazu Miki 4 , Kumiko Kagawa 1 , Shuji Ozaki 5 and Masahiro Abe 1 1 Department of Hematology, Endocrinology and Metabolism, Institute of Biomedical Sciences, Tokushima University...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30956773
DOI: 10.18632/oncotarget.26726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γPMID 30956773Read ↗

Targeting NF-κB Signaling for Multiple MyelomaSemantic proximity Read ↗

Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive ReviewSemantic proximity Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.Semantic proximity Read ↗

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaSemantic proximity Read ↗

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class ISemantic proximity Read ↗

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaSemantic proximity Read ↗

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myelomaSemantic proximity Read ↗

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomideSemantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myelomaSemantic proximity Read ↗

Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.